Total trials
809
Active
198
Phase 3
61
Total enrollment
397,184
Pipeline matrix
Showing 40 of 53 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ciprofloxacin | — | — | — | — | 2 | ||
| Midodrine | — | — | — | — | — | 2 | |
| Tezepelumab | — | — | — | — | — | 1 | |
| Sotatercept | — | — | — | — | — | 1 | |
| Envarsus Oral Product | — | — | — | — | — | 1 | |
| Prograf | — | — | — | — | — | 1 | |
| Isoproterenol Hydrochloride | — | — | — | — | — | 1 | |
| Norepinephrine Bitartrate | — | — | — | — | — | 1 | |
| Phenylephrine Hydrochloride | — | — | — | — | 4 | ||
| Propranolol Hydrochloride | — | — | — | — | 2 | ||
| Phentolamine Mesylate | — | — | — | — | 2 | ||
| Taurine | — | — | — | — | 2 | ||
| Furosemide | — | — | — | — | 3 | ||
| 18F-DOPA | — | — | — | — | — | 2 | |
| Ketorolac | — | — | — | — | 2 | ||
| 5-Hydroxytryptophan 100 MG | — | — | — | — | — | 1 | |
| 5-Hydroxytryptophan | — | — | — | — | — | 1 | |
| Carbidopa | — | — | — | — | — | 1 | |
| 18F-PSMA-1007 | — | — | — | — | — | 1 | |
| Metformin 850 mg oral tablet bid | — | — | — | — | — | 1 | |
| Lyophilized fecal microbiota | — | — | — | — | — | 1 | |
| Inhaled Nitric Oxide | — | — | — | — | — | 1 | |
| Empagliflozin | — | — | — | — | — | 1 | |
| Ranolazine | — | — | — | — | — | 1 | |
| 68Ga-HA-DOTATATE | — | — | — | — | — | 1 | |
| Treatment with blinatumomab given subcutaneously. | — | — | — | — | — | 1 | |
| MTX228 | — | — | — | — | — | 1 | |
| autologous CD19-directed chimeric antigen receptor (CAR) T-cells | — | — | — | — | — | 1 | |
| Ferumoxytol | — | — | — | — | — | 1 | |
| Dobutamine | — | — | — | — | — | 1 | |
| Vericiguat | — | — | — | — | — | 1 | |
| Exertional Oxygen | — | — | — | — | — | 1 | |
| Sildenafil Citrate | — | — | — | — | — | 1 | |
| Caffeine citrate | — | — | — | — | — | 1 | |
| Treprostinil Inhalation Solution 36 mcg | — | — | — | — | — | 1 | |
| Treprostinil Inhalation Solution 78 mcg | — | — | — | — | — | 1 | |
| Metformin | — | — | — | 4 | |||
| Vasopressin | — | — | — | — | 2 | ||
| Fish Oil and Metformin | — | — | — | — | — | 2 | |
| Epinephrine | — | — | — | — | — | 1 |
13 more active programs hidden
Next readouts
- 2026-01-13
- 2026-06-01
- 2026-06-30
- 2026-06-30
- 2026-07
- 2026-07-31
- 2026-08
- 2026-09
- 2026-09-01
- 2026-10
Top conditions
- Heart Failure18
- Breast Cancer13
- Type 1 Diabetes13
- Stroke13
- Obesity12
- Diabetes Mellitus, Type 211
- Hypertension10
- Congenital Heart Disease10
Frequently asked questions about University of Alberta
- How many clinical trials does University of Alberta have on ClinicalTrials.gov?
- University of Alberta is listed as the lead sponsor on 809 clinical trials in ClinicalTrials.gov, 198 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Alberta's trials are in Phase 3?
- 61 of University of Alberta's trials are in Phase 3, spread across 53 active drug programs.
- What therapeutic areas does University of Alberta focus on?
- University of Alberta's most-studied conditions on ClinicalTrials.gov are Heart Failure, Breast Cancer, Type 1 Diabetes, Stroke, Obesity.
- When are University of Alberta's next clinical trial readouts?
- University of Alberta has 10 upcoming primary-completion readouts tracked here; the soonest is “Vasopressin vs. Epinephrine During Neonatal Cardiopulmonary Resuscitation”, expected around 2026-01-13.